A Phase III, Multicenter, Rancomized Open-Label Study Evaluating the Efficacy and Safety of MPD3280A (Anti-PD-L1 Antibody)in Combination with Carboplatin + NAB-Paclitaxel for Chemotherapy-Naive Patients with Stage IV NSCLC

Administered By

Awarded By

Contributors

Start/End

  • August 1, 2015 - December 30, 2020